BACKGROUND: Transcatheter Aortic Valve Implantation (TAVI) has changed the treatment paradigm of the aortic stenosis (AS). It has become the treatment of choice in patients with symptomatic AS and surgical high risk, and a valid alternative to surgical aortic valve replacement in patients with low and medium surgical risk. Despite numerous evidence on clinical results, indications and benefits, only a few studies analyse it from patient's perspective and the impact of TAVI on them. The objective of this study is to evaluate the experience of patients undergoing TAVI. METHODS: Cross-sectional, descriptive observational study in two Spanish hospitals, with a establish Nurse TAVI program, with 100 patients undergoing TAVI. A specific questionnaire was designed (VALVEX questionnaire) and a pilot study was conducted by a multidisciplinary team of doctors, nurses and patients. The questionnaire was given to patients at 30 days after TAVI procedure during the follow up at the TAVI nurse clinic. RESULTS: The study demonstrated a mean satisfaction of 9 for the TAVI program, with 96% of patients that would recommend TAVI to other patients. Patients scored a high satisfaction on the information received prior to the procedure. During the procedure and admission, the satisfaction was high in relation to the care received. During the follow up, satisfaction was high in relation to the role of the TAVI nurse, for the information and continuation of care during the procedure, in reducing anxiety, organising their admission and understanding the process. However, questions with less scores were related to hospital catering, delay between diagnosed and treatment, and patient decision-making process. CONCLUSION The evaluation of patient experience allows us to improve the information given to the patient during their TAVI process and it can also allow patients to be more relax, aware and prepared for the procedure. Continuous follow up enables monitoring of patient recovery and helps to discuss any doubts improving patient's satisfaction. The use of PREMs and PROMs associated to TAVI pathway combined with an active participation of the patient on the design of the questionnaire is essential for keeping the patient in the centre of the TAVI pathway.

Background: and Purpose Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year. Methods: We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020). Results: There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths. Conclusions During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT.